Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update

Camilla Evangelisti, Francesca Chiarini, James A. McCubrey, Alberto M. Martelli

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the clonal expansion of transformed T-cell precursors. Although T-ALL prognosis has significantly improved due to the development of intensive chemotherapeutic protocols, primary drug-resistant and relapsed patients still display a dismal outcome. In addition, lifelong irreversible late effects from conventional therapy are a growing problem for leukemia survivors. Therefore, novel targeted therapies are required to improve the prognosis of high-risk patients. The mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct multiprotein complexes, which are referred to as mTOR complex 1 (mTORC1) and mTORC2. These two complexes regulate a variety of physiological cellular processes including protein, lipid, and nucleotide synthesis, as well as autophagy in response to external cues. However, mTOR activity is frequently deregulated in cancer, where it plays a key oncogenetic role driving tumor cell proliferation, survival, metabolic transformation, and metastatic potential. Promising preclinical studies using mTOR inhibitors have demonstrated efficacy in many human cancer types, including T-ALL. Here, we highlight our current knowledge of mTOR signaling and inhibitors in T-ALL, with an emphasis on emerging evidence of the superior efficacy of combinations consisting of mTOR inhibitors and either traditional or targeted therapeutics.

Original languageEnglish
Article number1878
Pages (from-to)1-24
Number of pages24
JournalInternational Journal of Molecular Sciences
Volume19
Issue number7
DOIs
Publication statusPublished - Jun 26 2018

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
leukemias
T-cells
Sirolimus
inhibitors
prognosis
Neoplasms
therapy
T-Lymphoid Precursor Cells
Physiological Phenomena
Therapeutics
Multiprotein Complexes
cancer
protein synthesis
Autophagy
Cell proliferation
Nucleotides
Lipids
nucleotides
cues

Keywords

  • Combination therapy
  • mTOR
  • T-cell acute lymphoblastic leukemia
  • Targeted therapy

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. / Evangelisti, Camilla; Chiarini, Francesca; McCubrey, James A.; Martelli, Alberto M.

In: International Journal of Molecular Sciences, Vol. 19, No. 7, 1878, 26.06.2018, p. 1-24.

Research output: Contribution to journalReview article

Evangelisti, Camilla ; Chiarini, Francesca ; McCubrey, James A. ; Martelli, Alberto M. / Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 7. pp. 1-24.
@article{c080e72a763449ef9809c0c2f833bcb5,
title = "Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update",
abstract = "T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the clonal expansion of transformed T-cell precursors. Although T-ALL prognosis has significantly improved due to the development of intensive chemotherapeutic protocols, primary drug-resistant and relapsed patients still display a dismal outcome. In addition, lifelong irreversible late effects from conventional therapy are a growing problem for leukemia survivors. Therefore, novel targeted therapies are required to improve the prognosis of high-risk patients. The mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct multiprotein complexes, which are referred to as mTOR complex 1 (mTORC1) and mTORC2. These two complexes regulate a variety of physiological cellular processes including protein, lipid, and nucleotide synthesis, as well as autophagy in response to external cues. However, mTOR activity is frequently deregulated in cancer, where it plays a key oncogenetic role driving tumor cell proliferation, survival, metabolic transformation, and metastatic potential. Promising preclinical studies using mTOR inhibitors have demonstrated efficacy in many human cancer types, including T-ALL. Here, we highlight our current knowledge of mTOR signaling and inhibitors in T-ALL, with an emphasis on emerging evidence of the superior efficacy of combinations consisting of mTOR inhibitors and either traditional or targeted therapeutics.",
keywords = "Combination therapy, mTOR, T-cell acute lymphoblastic leukemia, Targeted therapy",
author = "Camilla Evangelisti and Francesca Chiarini and McCubrey, {James A.} and Martelli, {Alberto M.}",
year = "2018",
month = "6",
day = "26",
doi = "10.3390/ijms19071878",
language = "English",
volume = "19",
pages = "1--24",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "7",

}

TY - JOUR

T1 - Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update

AU - Evangelisti, Camilla

AU - Chiarini, Francesca

AU - McCubrey, James A.

AU - Martelli, Alberto M.

PY - 2018/6/26

Y1 - 2018/6/26

N2 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the clonal expansion of transformed T-cell precursors. Although T-ALL prognosis has significantly improved due to the development of intensive chemotherapeutic protocols, primary drug-resistant and relapsed patients still display a dismal outcome. In addition, lifelong irreversible late effects from conventional therapy are a growing problem for leukemia survivors. Therefore, novel targeted therapies are required to improve the prognosis of high-risk patients. The mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct multiprotein complexes, which are referred to as mTOR complex 1 (mTORC1) and mTORC2. These two complexes regulate a variety of physiological cellular processes including protein, lipid, and nucleotide synthesis, as well as autophagy in response to external cues. However, mTOR activity is frequently deregulated in cancer, where it plays a key oncogenetic role driving tumor cell proliferation, survival, metabolic transformation, and metastatic potential. Promising preclinical studies using mTOR inhibitors have demonstrated efficacy in many human cancer types, including T-ALL. Here, we highlight our current knowledge of mTOR signaling and inhibitors in T-ALL, with an emphasis on emerging evidence of the superior efficacy of combinations consisting of mTOR inhibitors and either traditional or targeted therapeutics.

AB - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the clonal expansion of transformed T-cell precursors. Although T-ALL prognosis has significantly improved due to the development of intensive chemotherapeutic protocols, primary drug-resistant and relapsed patients still display a dismal outcome. In addition, lifelong irreversible late effects from conventional therapy are a growing problem for leukemia survivors. Therefore, novel targeted therapies are required to improve the prognosis of high-risk patients. The mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct multiprotein complexes, which are referred to as mTOR complex 1 (mTORC1) and mTORC2. These two complexes regulate a variety of physiological cellular processes including protein, lipid, and nucleotide synthesis, as well as autophagy in response to external cues. However, mTOR activity is frequently deregulated in cancer, where it plays a key oncogenetic role driving tumor cell proliferation, survival, metabolic transformation, and metastatic potential. Promising preclinical studies using mTOR inhibitors have demonstrated efficacy in many human cancer types, including T-ALL. Here, we highlight our current knowledge of mTOR signaling and inhibitors in T-ALL, with an emphasis on emerging evidence of the superior efficacy of combinations consisting of mTOR inhibitors and either traditional or targeted therapeutics.

KW - Combination therapy

KW - mTOR

KW - T-cell acute lymphoblastic leukemia

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85049133695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049133695&partnerID=8YFLogxK

U2 - 10.3390/ijms19071878

DO - 10.3390/ijms19071878

M3 - Review article

AN - SCOPUS:85049133695

VL - 19

SP - 1

EP - 24

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 7

M1 - 1878

ER -